Amarin | AMRN - Current Liabilities

Stock Price
15.34
Daily Change
-1.03 -6.29%
Monthly
-1.92%
Yearly
85.36%
Q1 Forecast
14.88

Amarin reported $182.23M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025